Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Pharma (IGC) over the last 17 years, with Q2 2025 value amounting to $4.7 million.

  • Pharma's Share-based Compensation rose 106915.42% to $4.7 million in Q2 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 39077.84%. This contributed to the annual value of $4.3 million for FY2025, which is 14252.68% up from last year.
  • Pharma's Share-based Compensation amounted to $4.7 million in Q2 2025, which was up 106915.42% from $3.5 million recorded in Q4 2024.
  • Pharma's 5-year Share-based Compensation high stood at $4.7 million for Q2 2025, and its period low was $125000.0 during Q2 2021.
  • Its 5-year average for Share-based Compensation is $938117.6, with a median of $523000.0 in 2021.
  • As far as peak fluctuations go, Pharma's Share-based Compensation plummeted by 6901.04% in 2023, and later soared by 106915.42% in 2025.
  • Pharma's Share-based Compensation (Quarter) stood at $523000.0 in 2021, then fell by 7.46% to $484000.0 in 2022, then grew by 8.68% to $526000.0 in 2023, then soared by 564.64% to $3.5 million in 2024, then soared by 34.44% to $4.7 million in 2025.
  • Its last three reported values are $4.7 million in Q2 2025, $3.5 million for Q4 2024, and $402000.0 during Q3 2024.